Årsredovisning 2023

Fulltext

===== SIDA 1 =====

Annual Financial Report
20 February 2024 11:00 GMT
Annual Financial Report
AstraZeneca
 
PLC
 
(the
 
Company)
 
announced
 
today
 
the
 
publication
 
of
 
its
 
Annual
 
Report
 
and
Form 20-F Information 2023 (the Annual Report).
A
 
copy
 
of
 
the
 
Annual
 
Report
 
will
 
be
 
submitted
 
to
 
the
 
National
 
Storage
 
Mechanism
 
and
 
will
shortly be available for inspection at 
http://data.fca.org.uk/#/nsm/nationalstoragemechanism
.
The Annual Report is also available on the Company's website 
www.astrazeneca.com
.
The Annual Report will be dispatched to shareholders in due course.
The
 
Company's
 
Annual
 
General
 
Meeting
 
(AGM)
 
will
 
take
 
place
 
on
 
11
 
April
 
2024.
 
The
 
Notice
 
of
AGM
 
and
 
Shareholders'
 
Circular
 
will
 
be
 
published
 
and
 
distributed
 
to
 
shareholders
 
in
 
due
course.
EXPLANATORY NOTE
For
 
the
 
purposes
 
of
 
complying
 
with
 
the
 
Disclosure
 
and
 
Transparency
 
Rules,
 
the
 
Annual
 
Report
being
 
submitted
 
to
 
the
 
National
 
Storage
 
Mechanism
 
contains
 
the
 
following
 
regulated
information in unedited form:
-     the principal risks and uncertainties facing the Company;
-
     
the
 
Directors'
 
responsibility
 
statement
 
made
 
in
 
respect
 
of
 
the
 
Financial
 
Statements
     
        and Directors' Report contained in the Annual Report; and
-     a statement regarding related party transactions.
AstraZeneca
AstraZeneca
 
(LSE/STO/Nasdaq:
 
AZN)
 
is
 
a
 
global,
 
science-led
 
biopharmaceutical
 
company
that
 
focuses
 
on
 
the
 
discovery,
 
development,
 
and
 
commercialisation
 
of
 
prescription
 
medicines
 
in
Oncology,
 
Rare
 
Diseases,
 
and
 
BioPharmaceuticals,
 
including
 
Cardiovascular,
 
Renal
 
&
Metabolism,
 
and
 
Respiratory
 
&
 
Immunology.
 
Based
 
in
 
Cambridge,
 
UK,
 
AstraZeneca
 
operates
in
 
over
 
100
 
countries
 
and
 
its
 
innovative
 
medicines
 
are
 
used
 
by
 
millions
 
of
 
patients
 
worldwide.
Please visit 
astrazeneca.com
 and follow the Company on social media 
@AstraZeneca
.
Contacts
For
 
details
 
on
 
how
 
to
 
contact
 
the
 
Investor
 
Relations
 
Team,
 
please
 
click
 
here
.
 
For
 
Media
contacts, click 
here
.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is
approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information
may apply. For further information, please contact 
rns@lseg.com
 or visit 
www.rns.com
.